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The carbon monoxide transfer factor (TLCO)
is widely used in lung function laboratories where
it complements the measurement of lung volumes
and of forced inspiratory and expiratory flows. The
TLCO is alternatively named the diffusing capac-
ity (DLCO), but the former term is more appro-
priate for two reasons. First, this index is not
uniquely determined by the diffusive characteris-
tics of the lung, and second, it does not represent
a maximal capacity in resting conditions because it
easily increases with metabolic rate [1]. By mea-
suring the surface area of the lung available for gas
exchange, this test represents a unique window on
the pulmonary microcirculation. Thus, the TLCO
is a key measurement in conditions like interstitial
lung diseases and in the evaluation before surgery
for lung cancer or for lung volume reduction in
emphysema. Furthermore, in the presence of nor-
mal lung volumes and spirometry, the TLCO may
be the sole abnormal test hinting to a pulmonary
vascular disorder like chronic thromboembolic
disease or other causes of pulmonary vascular
obliteration.
Although the usefulness of the TLCO is not
disputed, the complexity of this test is not always
fully appreciated. For instance, although intro-
duced long ago by Marie Krogh in 1915 [2], this
test was still fuelling a lively scientific controversy
at the dawn of the XXI century! [3–5]. The aim of
this article is first to recall some neglected princi-
ples of the TLCO, and second to propose a practi-
cal scheme of interpretation which is largely in-
spired by the thorough work of Hughes and Pride
[4, 6].
The transfer factor for carbon monoxide
(TLCO) is widely used in pulmonary function lab-
oratories because it represents a unique non-inva-
sive window on pulmonary microcirculation. The
TLCO is the product of two primary measure-
ments, the alveolar volume (VA) and the CO trans-
fer coefficient (KCO). This test is most informa-
tive when VA and KCO are examined, together
with their product TLCO. In a normal lung, a low
VA due to incomplete expansion is associated with
an elevated KCO, resulting in a mildly reduced
TLCO. Thus, in case of low VA, a seemingly “nor-
mal KCO” must be interpreted as an abnormal gas
transfer. The most common clinical conditions as-
sociated with an abnormal TLCO are characterised
by a limited number of patterns for VA and KCO:
incomplete lung expansion, discrete loss of alveo-
lar units, diffuse loss of alveolar units, emphysema,
pulmonary vascular disorders, high pulmonary
blood volume, alveolar haemorrhage.
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Summary
Introduction
Glossary:
CO: carbon monoxide
TLCO: carbon monoxide transfer factor (synonym: 
DLCO = carbon monoxide diffusing capacity)
TLCOSB: TLCO measured by the single-breath method 
kCO: rate constant for alveolar-capillary CO transfer
(= permeability factor)
KCO: carbon monoxide transfer coefficient
VA: alveolar volume
TLC: total lung capacity
DM: membrane conductance
q: rate of reaction of CO with haemoglobin
Qc: pulmonary capillary blood volume
PB: barometric pressure
PH2O: water vapour pressure
STPD: standard temperature (0 oC) and 
pressure (760 mm Hg), dry
BTPS: body temperature (37oC) and pressure (PB) 
saturated with water vapour
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The TLCO measures the rate of transfer of
CO from the alveoli to the blood. Inhaled carbon
monoxide is used because of its very high affinity
for haemoglobin: as a result, the plasma CO par-
tial pressure remains close to zero, the gradient of
partial pressure remains operational between the
alveoli and the capillary blood, and the amount of
CO transferred is limited by diffusion only. The
single-breath TLCO measurement (TLCOSB) was
introduced by Ogilvie et al. [7] and will be de-
scribed here because it is the most widely used
method.
The subject first fully exhales, then takes a
rapid and full inspiratory vital capacity of a gas mix-
ture composed of air, a tiny fraction of CO (0.003)
and a fraction of an inert gas such as helium or
methane. The breath is held for 10 seconds at com-
plete inspiration before a rapid and full exhalation
is made. After the first portion of exhaled gas has
been discarded, gas is collected during mid-expi-
ration as an alveolar sample for analysis of CO and
of the inert gas. It is very important to control the
quality of the manoeuvre by checking several
points: that the inspiration is rapid enough (<2.5 s,
or <4 s in case of airflow limitation), that the in-
spired volume is large enough (>90% vital capac-
ity), and that the breath-holding time is correct 
(10 ± 1 s). From this, two primary measurements
are made:
Rate constant for alveolar-capillary CO 
transfer (= permeability factor, kCO):
The initial alveolar fraction of CO is calcu-
lated as follows:
FACO0 = FICO · (FAHe / FIHe)
where: FICO = inspired fraction of CO
FAHe = alveolar fraction of helium
FIHe = inspired fraction of helium
During breath-holding, the alveolar fraction
of CO decreases exponentially:
FACOt = FACO0 · e–kt
The permeability factor is calculated as fol-
lows:
loge (FACO0 / FACOt)
kCO = 
t
where the unit for kCO is: min–1
Alveolar volume (VA):
FIHe
VA = VI ·
FAHe
where: VI = inspired volume
the unit for VA is: ml STPD
The TLCO is then calculated as the product 
of the permeability factor and alveolar volume, 
divided by the effective barometric pressure:
kCO · VA
TLCO = 
PB – PH2O
where: PB = barometric pressure
PH2O = water vapour pressure
The TLCO is expressed in units of conduc-
tance: 
mmol CO · min–1 · kPa–1 (or ml CO · min–1 ·
mm Hg–1 in traditional units).
It is important to understand that the TLCO
is not the measurement of an actual physical vari-
able. Rather, it is a calculation of what would be
the flux of CO from the alveoli to the blood in the
hypothetical condition of the subject’s lungs being
filled with 100% CO (which, if true, would expose
to medico-legal consequences). Hence the intro-
duction of alveolar volume which represents the
volume of distribution of CO, and of barometric
pressure which corresponds to the driving pressure
for diffusion [6].
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Measurement
Theoretical considerations
Components of TLCO
The TLCO is made of two conductances in se-
ries: the membrane conductance (DM) which repre-
sents the diffusion component, and the reactive con-
ductance (q · Qc) where q is the rate of reaction of
CO with haemoglobin and Qc is the blood volume
in the pulmonary capillaries. The DM factor is re-
duced when the alveolar-capillary membrane sur-
face is reduced or when its thickness is increased.
The q factor varies with the concentration of
haemoglobin: the low value of q explains the low
values of TLCO measured in anaemia [8].
Confounding factors
Because of the effect of haemoglobin concen-
tration [Hb], TLCO has to be adjusted to the nor-
mal [Hb] in particular when anaemia is present or
can be suspected. The adjusted value (TLCO adj.
or TLCO corr.) is considered for assessing gas
exchange.
Carboxyhaemoglobin (HbCO) reduces TLCO
by two mechanisms: first, it decreases the CO pres-
sure gradient by increasing venous CO back pres-
sure, and second, it decreases the mass of haemo-
globin available for CO binding. The effect is a 1%
fall of TLCO for each 1% increment of [HbCO].
To avoid this problem it is recommended that the
subject refrains from smoking 24 hours before the
test.
The TLCO is influenced by altitude because
oxygen and CO are in competition for Hb: q in-
creases when alveolar PO2 falls. Thus, TLCO in-
creases by 0.31% per mm Hg decrease in inspired
PO2. This point has to be considered when the test
is performed in a pulmonary function laboratory
located at high altitude.
Exercise increases TLCO by increasing pul-
monary capillary blood volume (Qc). Thus, TLCO
increases by 20% for each increment of 5 L · 
min–1 of cardiac output. It is recommended that 
the subject refrains from strenuous exercise and
remains seated for at least 5 min before testing [9].
The problem of VA in airflow limitation
Patients with chronic obstructive pulmonary
disease (COPD), in particular those with emphy-
sema, tend to have a higher than normal total lung
capacity (TLC). Yet, the alveolar volume (VA)
measured during the TLCOSB manoeuvre is low.
This discrepancy between VA and TLC is due to
uneven ventilation distribution during the short
breath-holding time leading to an incomplete mix-
ing between the inspired gas and the residual vol-
ume gas. Indeed, the more severe is airflow limita-
tion, the higher is the underestimation of TLC by
VA. As TLCO is the product of kCO and VA divided
by effective barometric pressure, this results in an
underestimation of the potential true TLCO of the
patient. However, the degree of underestimation
is unknown, because poorly ventilated units are
likely to be more severely affected by the disease.
This is an inherent limitation of the TLCOSB in
COPD. To circumvent this problem it has been
proposed to use the VA measured by plethysmog-
raphy [1]. However, this would lead to an overes-
timation of true TLCO because it would include
poorly ventilated units and assign them a kCO
equal to that of well ventilated units [4]. Moreover,
this dual method is impractical and is consequently
not applied.
What is KCO (or TLCO/VA)?
The carbon monoxide transfer coefficient
(KCO) is often written as TLCO divided by alve-
olar volume (TLCO/VA). It is important to grasp
what KCO actually represents. If we take the equa-
tion for TLCO:
kCO · VA
TLCO = 
PB – PH2O
then, dividing by VA:
kCO · VA kCO
KCO = TLCO/VA = =
(PB – PH2O) · VA PB – PH2O
the units for KCO are: mmol CO · min–1 · 
kPa–1 · L–1, or ml CO · min–1 · mm Hg–1 · L–1 in 
traditional units. In the latter case, note that VA
is expressed in ml STPD in the numerator because
it represents a volume of CO, and in L BTPS in
the denominator because it represents a volume of
air.
Thus, the transfer coefficient KCO is simply an-
other way to express the permeability factor kCO,
one of the two primary measurements allowing to
derive TLCO [4, 6].
The expression TLCO/VA is misleading be-
cause it implies a “correction of TLCO for alveo-
lar volume”. According to this view, a low TLCO
with a low VA and a normal KCO (or TLCO/VA)
would be interpreted as a lung of reduced volume
but with normal transfer of CO. This is definitely
wrong because in a normal lung, KCO increases
exponentially when alveolar volume is reduced, as
during a voluntary incomplete expansion, or dur-
ing a reduced expansion in a patient with a neuro-
muscular disorder (Figure 1). This is due to an in-
crease in the surface to volume ratio for diffusion
per alveolus as the alveoli become smaller. Thus,
when VA is low, a seemingly “normal KCO” actu-
ally reflects an abnormal gas transfer.
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Figure 1
Variation of carbon
monoxide transfer
coefficient (KCO) and
transfer factor (TLCO)
with lung expansion
in normal subjects.
The KCO, TLCO and
alveolar volume (VA)
are expressed in per-
cent of values mea-
sured at full inspira-
tion. The KCO in-
creases exponentially
with decreasing VA.
As a result, TLCO
decreases only mildly
with decreasing VA.
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Practical considerations for interpretation 
of TLCO
From the preceding considerations, it appears
that the interpretation of TLCO is unfortunately
not straightforward. Nevertheless, this test is
highly informative and useful if the following steps
are taken [6]:
First, the quality of the manoeuvres must be
scrupulously checked. This is now made easy by
the display of error codes. A common failure is an
insufficient inspired volume, whereas it should ex-
ceed 90% of vital capacity.
Second, KCO and VA should be considered as
the primary measurements and should be analysed
along with TLCO. The relationship between these
variables can be seen as follows:
KCO · VA = TLCO
efficiency per number of gas exchange
lung unit contributing units capacity
For practical purposes, the most common dis-
orders affecting TLCO can be grouped in a limited
number of pathophysiological or clinical entities.
1) Incomplete lung expansion
The lung is normal but incompletely inflated,
like in neuromuscular disorders, obesity, kypho-
scoliosis, pleural effusion, or in case of a poorly
performed test. The low VA is associated with an
elevated KCO. As a result, TLCO is only mildly
reduced, falling by 3% per 10% fall in VA.
Case 1: 57-year-old man, acid maltase defi-
ciency:
Vital capacity 50% pr. VA 64% pr.
Total lung capacity 65% pr. KCO 141% pr.
FEV1 52% pr. TLCO 91% pr.
FEV1/FVC 100% pr.
Case 2: 52-year-old woman, obesity (BMI = 
64 kg · m–2):
Vital capacity 84% pr. VA 63% pr.
Total lung capacity 72% pr. KCO 143% pr.
FEV1 61% pr. TLCO 91% pr.
FEV1/FVC 106% pr.
2) Discrete loss of alveolar units
There is a discrete loss of lung, for instance a
whole lung, a lobe, or several units in several lobes,
but the lung remaining is normal. Examples are
pneumonectomy, lobectomy, lobar collapse, local
destruction (post-TB, bronchiectasis), localized
alveolar infiltrate (sarcoidosis). The loss of alveo-
lar units is reflected by a low VA. Because blood
flow of lost units is diverted to remaining units,
KCO increases slightly. As a result, TLCO falls rel-
atively less than VA.
Case 3: 62-year-old man, post-pneumonec-
tomy (right lung):
Vital capacity 43% pr. VA 45% pr.
Total lung capacity 55% pr. KCO 110% pr.
FEV1 45% pr. TLCO 50% pr.
FEV1/FVC 104% pr.
3) Diffuse loss of alveolar units
The alveolar units most severely affected by
the disease are lost, but the remaining lung is af-
fected as well by the disease. Examples are diffuse
fibrosis (idiopathic pulmonary fibrosis, connective
tissue diseases, pneumoconiosis), alveolar infil-
trates (inflammatory infiltrate, hypersensitivity
pneumonitis, pneumocystis carinii pneumonia),
cardiovascular disorders (pulmonary oedema,
chronic heart failure). The VA is low, KCO is low
to “normal”, and TLCO is markedly reduced.
Case 4: 79-year-old man, pulmonary asbesto-
sis:
Vital capacity 59% pr. VA 47% pr.
Total lung capacity 60% pr. KCO 79% pr.
FEV1 65% pr. TLCO 37% pr.
FEV1/FVC 109% pr.
Case 5: 75-year-old man, idiopathic pulmo-
nary fibrosis:
Vital capacity 73% pr. VA 60% pr.
Total lung capacity 66% pr. KCO 98% pr.
FEV1 77% pr. TLCO 59% pr.
FEV1/FVC 105% pr.
Case 6: 73-year-old man, chronic heart failure:
Vital capacity 86% pr. VA 76% pr.
Total lung capacity 96% pr. KCO 80% pr.
FEV1 81% pr. TLCO 61% pr.
FEV1/FVC 95% pr.
Case 7: 45-year-old man, systemic lupus ery-
thematosus with interstitial lung infiltrate and di-
aphragm weakness:
Vital capacity 46% pr. VA 45% pr.
Total lung capacity 63% pr. KCO 104% pr.
FEV1 50% pr. TLCO 47% pr.
FEV1/FVC 109% pr.
Comment: the interstitial lung disease and the
diaphragm weakness both contribute to a low VA.
In case of diaphragm weakness with a normal lung,
the KCO would be elevated, whereas the seem-
ingly “normal” value observed here reflects the
effect of interstitial disease.
4) Obstructive lung disease
The VA is low because of incomplete mixing
between the inspired gas and the residual volume
gas during the short breath-holding time. The
KCO differs according to the underlying disease.
In emphysema, KCO is low because of the loss of
alveolar-capillary surface. As a result, TLCO is se-
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verely reduced. In contrast, KCO may be increased
in asthma where the pulmonary microcirculation
is preserved and cardiac output may be increased.
Case 8: 76-year-old man, pulmonary emphy-
sema:
Vital capacity 68% pr. VA 65% pr.
Total lung capacity 118% pr. KCO 26% pr.
FEV1 30% pr. TLCO 17% pr.
FEV1/FVC 44% pr.
5) Pulmonary vascular disorders
Examples are pulmonary arterial hyperten-
sion, chronic thromboembolic pulmonary hyper-
tension, vasculitis, sickle-cell disease, hepatopul-
monary syndrome. The VA is normal or near nor-
mal, KCO is reduced due to the vascular disorder,
and TLCO is reduced approximately to the same
degree.
Case 9: 52-year-old woman, chronic throm-
boembolic pulmonary hypertension:
Vital capacity 123% pr. VA 98% pr.
Total lung capacity 105% pr. KCO 56% pr.
FEV1 101% pr. TLCO 55% pr.
FEV1/FVC 88% pr.
Case 10: 24-year-old woman, Takayasu’s dis-
ease:
Vital capacity 88% pr. VA 84% pr.
Total lung capacity 95% pr. KCO 74% pr.
FEV1 79% pr. TLCO 62% pr.
FEV1/FVC 95% pr.
6) Increased pulmonary blood volume
Both KCO and TLCO are mildly to moder-
ately increased when pulmonary capillary blood
volume is increased, as in case of high cardiac out-
put or of left-to-right shunt.
7) Alveolar haemorrhage
Intermittent alveolar haemorrhage occurs in
anti-GBM disease, pulmonary vasculitis, systemic
lupus erythematosus, and idiopathic haemosidero-
sis. The VA is mildly reduced by alveolar filling
with blood, and KCO is markedly increased be-
cause inhaled CO reacts with extravascular haemo-
globin. The KCO often increases to more than
150% of predicted, and a 30% increase in KCO
over baseline values is suggestive of alveolar haem-
orrhage [10]. After haemorrhage ceases, the half-
time of the return of KCO to baseline is 24 hours.
It is essential to adjust KCO and TLCO to a nor-
mal haemoglobin concentration because of fluctu-
ating anaemia in these patients [6].
Thus, by analysing VA, KCO and TLCO to-
gether one is able to discriminate between the most
common abnormal patterns (Table 1). Although
not straightforward, this analysis of TLCO is worth
the effort because major therapeutic decisions may
depend on this test, like performing surgery or ini-
tiating immunosuppressive or cytostatic therapy.
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Condition VA KCO TLCO
Incomplete lung expansion 444 22 4
Discrete loss of alveolar units 444 2 44
Diffuse loss of alveolar units 44 4 444
Pulmonary emphysema 4 44 444
Pulmonary vascular disorders normal 44 44
High pulmonary blood volume normal 2 2
Alveolar haemorrhage 4 222 22
Single-breath method. VA: alveolar volume; KCO: carbon monoxide transfer coefficient; TLCO: carbon monoxide transfer factor.
Table 1
Common abnormal
patterns of carbon
monoxide transfer
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